- Home
- HCA vs REGN Comparison
HCA vs REGN Comparison
Compare HCA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCA
- REGN
- Stock Information
- Founded
- HCA 1968
- REGN 1988
- Country
- HCA United States
- REGN United States
- Employees
- HCA N/A
- REGN N/A
- Industry
- HCA Hospital/Nursing Management
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- HCA Health Care
- REGN Health Care
- Exchange
- HCA Nasdaq
- REGN Nasdaq
- Market Cap
- HCA 93.8B
- REGN 110.0B
- IPO Year
- HCA N/A
- REGN 1991
- Fundamental
- Price
- HCA $303.90
- REGN $701.85
- Analyst Decision
- HCA Buy
- REGN Buy
- Analyst Count
- HCA 15
- REGN 24
- Target Price
- HCA $381.29
- REGN $1,054.00
- AVG Volume (30 Days)
- HCA 1.4M
- REGN 851.0K
- Earning Date
- HCA 01-28-2025
- REGN 01-31-2025
- Dividend Yield
- HCA 0.87%
- REGN N/A
- EPS Growth
- HCA 9.31
- REGN 15.31
- EPS
- HCA 22.31
- REGN 40.43
- Revenue
- HCA $69,621,000,000.00
- REGN $13,847,100,000.00
- Revenue This Year
- HCA $9.61
- REGN $10.20
- Revenue Next Year
- HCA $6.08
- REGN $4.16
- P/E Ratio
- HCA $13.61
- REGN $17.36
- Revenue Growth
- HCA 10.23
- REGN 5.72
- 52 Week Low
- HCA $268.01
- REGN $693.00
- 52 Week High
- HCA $417.14
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- HCA 19.25
- REGN 27.80
- Support Level
- HCA $310.50
- REGN $693.00
- Resistance Level
- HCA $317.08
- REGN $745.00
- Average True Range (ATR)
- HCA 7.01
- REGN 21.29
- MACD
- HCA -0.50
- REGN 0.05
- Stochastic Oscillator
- HCA 5.40
- REGN 8.20
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).